China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Report 2022 to 2030

China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Analysis

$ 3999

China's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $297 Mn in 2022 to $721 Mn in 2030 with a CAGR of 11.70% for the year 2022-30. Since eculizumab, a drug used to treat PNH is now available in China, many patients are starting to express interest in using targeted therapy to treat rare diseases. The market for PNH therapies in China is anticipated to increase as a result of this tendency. The market is segmented by therapy, diagnostic test, and distribution channels. Some key players in this market include Sinopharm Group, Shanghai Pharmaceuticals, Jiangsu Hengrui Medicine, Amgen, CSL Behring, and Bioverativ.

ID: IN10CNPH312 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Jigyasu Bhandari

Buy Now

China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Executive Analysis

China's Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is expected to grow from $297 Mn in 2022 to $721 Mn in 2030 with a CAGR of 11.70% for the year 2022-30. In China as a whole, healthcare costs exceeded $1.987 trillion in 2022. In 2021, more than 1.689 people received access to affordable health insurance for the first time. In 2022, more than 97.87% of the population had access to health insurance.

In 2022, it was expected that between 250 and 490 People with PNH would reside in China. Hemolysis, or the disintegration of red blood cells, is caused by Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare and deadly blood condition. PNH is a rare condition in China, and there are no extensive national registries, making diagnosis and treatment difficult. Clinical signs, lab testing, and blood cell flow cytometry analysis are the main criteria used in China to diagnose PNH. The non-specific symptoms of the illness, which might mirror those of other hematological illnesses, may make the diagnosis difficult. Furthermore, in some parts of China, the availability of specialized testing and expertise may be constrained. In China, treating the disease's symptoms and avoiding complications are the main goals of PNH treatment. China has authorized the use of eculizumab, a monoclonal antibody that inhibits the complement cascade and lessens hemolysis, for the treatment of PNH. The drug's availability may be restricted to specific areas or hospitals due to the expensive cost. Other supportive treatments, including blood transfusions, iron chelation therapy, and hematopoietic stem cell transplantation, may also be used in China in addition to eculizumab to treat the symptoms and side effects of PNH.

china paroxysmal nocturnal hemoglobinuria therapeutics market

Market Dynamics

Market Growth Drivers

Since eculizumab, a drug used to treat PNH is now available in China, many patients are starting to express interest in using targeted therapy to treat rare diseases. The market for PNH therapies in China is anticipated to increase as a result of this tendency. It is anticipated that more patients in China will be diagnosed with PNH as medical professionals and the general public become more aware of the condition. The market for PNH drugs will consequently grow. Spending on healthcare has increased in China recently, with a focus on improving the standard and accessibility of healthcare services. As a result, China is expected to invest more money in developing and making PNH drugs available.

Market Restraints

PNH is a rare condition, and China has fewer PNH patients than most other nations. This might reduce the demand for PNH treatments and deter manufacturers from making investments in this field. The most popular treatment for PNH, eculizumab, is a pricey medication, and the high cost of care may restrict the accessibility and use of PNH therapies in China.

Competitive Landscape

Key Players

Sinopharm Group (CN)
Shanghai Pharmaceuticals (CN)
Jiangsu Hengrui Medicine (CN)
Achillion Pharmaceuticals
Novartis International
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Akari Therapeutics
Amgen
CSL Behring
Bioverativ

Healthcare Policies and Regulatory Landscape

The National Medical Products Administration (NMPA), which analyses and authorizes new pharmaceuticals for the market, is the regulatory body in China in charge of drug approval. There have been initiatives to speed up the medication approval procedure for therapies for rare diseases, including PNH, and the regulatory environment for rare diseases is still evolving in China. The Chinese government introduced a new policy in 2018 that sped up the licensing procedure for medicines created abroad, particularly those for uncommon disorders. This strategy intends to enhance the accessibility of innovative therapies for rare diseases in China and foster innovation in the biopharmaceutical sector. The Chinese government has also put rules in place to encourage the creation of novel medications, particularly therapies for uncommon diseases. The "Healthy China 2030" plan, which was introduced by the government in 2016, includes steps to support the creation of novel medications and the accessibility of cutting-edge therapies for uncommon diseases.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Segmentation

By Therapy

Medication Therapy
Stem Cell Therapy
Blood Transfusion Therapy

By Diagnostic Tests

CBC
LHD
Bone Marrow Examination
Flow Cytometry

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.